Vivo Opportunity, LLC has bought stock on 5 days since Jan 2022

Vivo Opportunity, LLC is a corporate investment vehicle associated with Vivo Capital, a global healthcare-focused investment firm that manages dedicated public-equity strategies through its Vivo Opportunity Fund platform.( As a 10% owner in InMed Pharmaceuticals Inc. (INM), Vivo Opportunity, LLC functions as an institutional shareholder, reflecting Vivo Capital’s mandate to invest in small- and mid‑cap life sciences companies developing innovative therapeutics and medical technologies.( Public filings identify Vivo Opportunity, LLC as a legal entity rather than an individual, indicating its role as a specialized fund or affiliate used for public‑market healthcare investments.(

Vivo Capital, founded in 1996 and headquartered in Palo Alto, California, operates a multi‑fund platform spanning venture capital, growth equity, buyouts, and public equity, with a sole focus on healthcare and life sciences.( Through its public fund complex—branded as the Vivo Opportunity Fund and affiliates—the firm has raised more than $740 million in commitments for public‑equity strategies, targeting preclinical and clinical‑stage life sciences companies addressing unmet medical needs.( Vivo Capital oversees approximately $5.3 billion in regulatory assets under management and has completed over 430 investments globally, supported by a team of more than 75 professionals across the U.S. and Asia.( Vivo Opportunity, LLC operates within this platform, providing structured exposure to public healthcare equities such as InMed Pharmaceuticals.(

Written by Perplexity from public sources.